Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Occupational Exposure

The legacy theme of general health and science information has long provided a foundation for public understanding of wellness and disease prevention. Within this broad context, discussions have historically centered on lifestyle factors, such as alcohol consumption during periods of societal stress, and their impact on physical and psychological well-being. This established framework emphasizes the importance of monitoring substance use and recognizing when habits may lead to adverse health outcomes. Transitioning from this general health perspective, a more specific occupational exposure concern emerges when considering the pharmaceutical agent Fosamax. In mass production environments, workers may encounter this medication during manufacturing, handling, or packaging processes. The scientific evidence connecting Fosamax to Osteonecrosis of the Jaw introduces a distinct risk profile that warrants careful attention. Unlike lifestyle-related health issues, this concern is tied directly to workplace exposure and the potential for unintended contact with the substance. The pivot from general health literacy to occupational safety highlights the need for rigorous protocols in production settings, ensuring that workers are protected from hazards that may not be immediately apparent in broader health discussions. This shift underscores the transition from population-level health advice to targeted, industry-specific risk management.

Understanding Fosamax and Its Mechanism

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence. However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves areas of exposed bone that persist for more than eight weeks, often accompanied by pain, swelling, infection, or drainage. Diagnosis is based on clinical examination and imaging, with exclusion of metastatic disease or other causes. ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Scientific Evidence Linking Fosamax to ONJ

The scientific evidence connecting Fosamax to ONJ is supported by pharmacological and mechanistic pathways. Bisphosphonates like alendronate accumulate in bone tissue, particularly in areas of high turnover such as the jaw. They inhibit osteoclast activity, which reduces bone remodeling. This suppression of normal bone turnover can impair the jawbone's ability to repair microdamage and respond to local stressors, such as dental procedures or infection. Multiscale characterization of jawbone in animal models has provided comprehensive information to help understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Studies in estrogen-deficient rats treated with alendronate have examined effects on jawbone properties, including mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings suggest that bisphosphonate treatment alters jawbone structure and function, potentially increasing vulnerability to ONJ. The timeline between Fosamax exposure and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experienced relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Causation Considerations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under warnings and precautions. This section states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and outlines associated risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that in placebo-controlled clinical studies, the percentages of patients with certain symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the label does not provide specific incidence rates for ONJ in the general osteoporosis population, which may limit patients' ability to assess their personal risk. For affected patients, causation-related considerations are complex. ONJ is a multifactorial condition, and Fosamax use is one of several risk factors. The presence of other risk factors, such as dental procedures, cancer, or concomitant medications, complicates attribution of causation solely to Fosamax. Nonetheless, the temporal relationship between drug initiation and ONJ onset, as well as recurrence upon rechallenge, supports a causal link in some cases. Patients who develop ONJ while on Fosamax should be evaluated for other risk factors, and discontinuation of the drug may be considered based on clinical judgment. In summary, scientific evidence from clinical reports, pharmacological studies, and mechanistic research supports a connection between Fosamax and osteonecrosis of the jaw. The risk is influenced by duration of use, dental procedures, and other patient factors. While warnings exist in the prescribing information, patients and healthcare providers should remain vigilant for signs of ONJ, especially in those with additional risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat osteoporosis by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk. It is approved for postmenopausal women, men with osteoporosis, glucocorticoid-induced osteoporosis, and Paget's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it diagnosed?

ONJ is a condition characterized by exposed, non-healing bone in the jaw that persists for more than eight weeks, often with pain, swelling, or infection. Diagnosis is based on clinical exam and imaging, excluding other causes (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is the scientific evidence linking Fosamax to ONJ?

Bisphosphonates like Fosamax accumulate in jawbone, inhibit osteoclast activity, and impair bone remodeling, increasing vulnerability to ONJ. Animal studies show altered jawbone properties (https://pubmed.ncbi.nlm.nih.gov/40345077/). Clinical data indicate ONJ onset from days to months after starting Fosamax, with recurrence upon rechallenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Are there adequate warnings about ONJ in Fosamax prescribing information?

Yes, the label includes a warning about ONJ and lists risk factors, but does not provide specific incidence rates for the general osteoporosis population (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.